FDA Grants a Priority Review To Gilead Sciences' Cancer Therapy
Today, Gilead Sciences (NASDAQ: GILD) disclosed its next cell-based cancer therapy could become available this summer. The Food and Drug Administration recently granted a priority review to an application Gilead submitted a couple of months ago for KTE-X19 with an expected action date of Aug. 10, 2019.
Gilead's potential new cancer therapy isn't exactly new. It's basically Yescarta with an improved manufacturing process that the company has aimed at a small segment of non-Hodgkin lymphoma patients. Yescarta and KTE-X19 are both CAR-T therapies made with cells harvested from patients that are trained to recognize cells with the CD19 antigen on their surface.
To get its hands on Yescarta and a handful of experimental CAR-T therapies in development, Gilead Sciences acquired Kite Pharma in 2017 for $11.9 billion.
Source Fool.com
